HTN Recommended dose: 4 mg once daily. Titrate dose according to response up to 16 mg once daily. Elderly >75 yr, moderate to severe renal impairment, mild to moderate hepatic impairment Initially 2 mg once daily. Titrate dose according to response. Heart failure Recommended initial dose: 4 mg once daily. Up-titration to the target dose of 32 mg once daily or the highest tolerated dose is done by doubling the dose at intervals of at least 2 wk.
View Blopress overdosage for action to be taken in the event of an overdose.
Administration
May be taken with or without food.
Contraindications
Hypersensitivity. Severe hepatic impairment &/or cholestasis. Combination w/ Aliskiren-containing medicine in patients w/ diabetes or moderate to severe renal impairment (GFR <60 mL/min/1.73 m2). Pregnancy & lactation.
Dual blockade of the renin-angiotensin-aldosterone system (RAAS) by combining Blopress & aliskiren is not recommended due to increased risk of hypotension, hyperkalemia & renal function changes. Periodic monitoring of serum K & creatinine levels is recommended in hypertensive patients w/ renal impairment. Thorough BP monitoring & careful titration of Blopress in patients w/ very severe or end-stage renal impairment or on haemodialysis. Include periodic renal function assessment in evaluation of patients w/ heart failure especially in elderly ≥75 yr. Renal function may worsen in patients w/ renal artery stenosis. Hypotension. Patients suffering from haemodynamically relevant aortic or mitral valve stenosis or obstructive hypertrophic cardiomyopathy. Not recommended in patients w/ primary hyperaldosteronism. Co-administration w/ K-sparing diuretics may result in increased K level. Patients w/ rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption should not take Blopress. Dizziness or weariness may occur during treatment. Not to be used in pregnancy. Discontinue treatment if pregnancy is detected. Not to be given during breast-feeding. Childn & adolescents <18 yr.
Dizziness/vertigo, headache; resp infection. Increases in creatinine, urea or K & decrease in Na. Heart failure: Hypotension; hyperkalaemia; renal impairment.
Antihypertensive effect may be enhanced by other antihypertensives. Increase in serum K w/ K-sparing diuretics, K supplements, K-containing salt substitutes or other drugs that may increase K levels (eg, heparin). Reversible increase in serum lithium conc & toxicity during concomitant use of lithium w/ ACE inhibitors. Antihypertensive effect may be attenuated by NSAIDs eg, indomethacin, selective COX-2 inhibitors, ASA & non-selective NSAIDs. Increased risk of worsening renal function w/ concomitant use of AIIA & NSAIDs.
Sign Out
